<div id="readability-page-1"><p><span>CONMED (NYSE:CNMD - Get Free Report)</span> was upgraded by equities researchers at Wall Street Zen from a &#34;buy&#34; rating to a &#34;strong-buy&#34; rating in a research note issued on Tuesday.</p><ul><li>Med-tech stock Conmed dips ahead of big Q4 report...opportunity?</li></ul><p>CNMD has been the topic of several other research reports. Needham &amp; Company LLC  reaffirmed a &#34;hold&#34; rating on shares of CONMED in a report on Thursday, January 29th. Weiss Ratings  reaffirmed a &#34;sell (d+)&#34; rating on shares of CONMED in a report on Wednesday, January 21st. Zacks Research raised CONMED from a &#34;strong sell&#34; rating to a &#34;hold&#34; rating in a report on Tuesday, February 3rd. Piper Sandler cut CONMED from an &#34;overweight&#34; rating to a &#34;neutral&#34; rating and lowered their price target for the company from $55.00 to $39.00 in a report on Tuesday, March 17th. Finally, Wells Fargo &amp; Company raised CONMED to a &#34;hold&#34; rating in a report on Wednesday, March 18th. Seven analysts have rated the stock with a Hold rating and one  has given a Sell rating to the company. Based on data from MarketBeat.com, CONMED presently has an average rating of &#34;Reduce&#34; and an average price target of $50.17.</p><p><b>Check Out Our Latest Stock Report on CNMD</b></p><h2>CONMED Stock Performance</h2><p>NYSE:CNMD opened at $38.47 on Tuesday. The business's 50-day moving average price is $39.59 and its two-hundred day moving average price is $41.79. CONMED has a twelve month low of $33.21 and a twelve month high of $61.08. The stock has a market cap of $1.16 billion, a P/E ratio of 25.48, a PEG ratio of 1.61 and a beta of 0.99. The company has a quick ratio of 1.01, a current ratio of 2.14 and a debt-to-equity ratio of 0.81. </p><p>CONMED (NYSE:CNMD - Get Free Report) last released its quarterly earnings results on Wednesday, January 28th. The company reported $1.43 earnings per share for the quarter, beating the consensus estimate of $1.32 by $0.11. CONMED had a return on equity of 14.23% and a net margin of 3.42%.The firm had revenue of $373.20 million for the quarter, compared to analysts' expectations of $366.88 million. During the same quarter last year, the firm posted $1.34 EPS. The company's revenue was up 7.9% compared to the same quarter last year.  As a group, equities analysts predict that  CONMED will post 4.35 EPS for the current fiscal year. </p><h2>Hedge Funds Weigh In On CONMED</h2><p>Several institutional investors have recently modified their holdings of the company. GAMMA Investing LLC increased its position in shares of  CONMED by 14.8% during the 3rd quarter. GAMMA Investing LLC now owns 1,770 shares of the company's stock valued at $83,000 after purchasing an additional 228 shares during the last quarter.  WINTON GROUP Ltd increased its position in shares of  CONMED by 0.3% during the 4th quarter. WINTON GROUP Ltd now owns 78,887 shares of the company's stock valued at $3,203,000 after purchasing an additional 260 shares during the last quarter.  Amalgamated Bank increased its position in shares of  CONMED by 3.3% during the 3rd quarter. Amalgamated Bank now owns 9,129 shares of the company's stock valued at $429,000 after purchasing an additional 294 shares during the last quarter.  Rockefeller Capital Management L.P. increased its position in shares of  CONMED by 48.6% during the 4th quarter. Rockefeller Capital Management L.P. now owns 1,043 shares of the company's stock valued at $42,000 after purchasing an additional 341 shares during the last quarter.  Finally, Keeler Thomas Management LLC grew its position in  CONMED by 1.6% during the 3rd quarter. Keeler Thomas Management LLC now owns 21,107 shares of the company's stock worth $993,000 after acquiring an additional 342 shares during the last quarter. </p><h2>CONMED Company Profile</h2> (Get Free Report)<p>CONMED Corporation <span>NYSE: CNMD<span></span></span> is a global medical technology company headquartered in Utica, New York. Founded in 1970, CONMED develops, manufactures and markets a broad portfolio of surgical devices and accessories for minimally invasive procedures. The company's product line supports surgeons and healthcare providers in specialties including orthopedics, general surgery, gastroenterology and gynecology.  </p><p>CONMED operates two principal segments: Orthopedics, and Visualization &amp; Energy.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than CONMED</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUNOTUQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="600" height="385" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUNOTUQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in CONMED Right Now?</h2><p>Before you consider CONMED, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CONMED wasn't on the list.</p><p>While CONMED currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

CNMD

<p>Wall Street Zen upgraded CONMED (NYSE:CNMD) from a "buy" to a "strong-buy" rating. The stock has seen mixed ratings from other analysts, with Needham maintaining a "hold" and Weiss Ratings giving a "sell". CONMED's current stock price is $38.47, with a market cap of $1.16 billion. The company reported earnings of $1.43 per share, exceeding estimates, and a revenue increase of 7.9% year-over-year. Analysts predict an EPS of 4.35 for the current fiscal year.</p>

CONMED (NYSE:CNMD) Upgraded to Strong-Buy at Wall Street Zen